[1]刘婕妤,方智辉,李文克,等.复方磺胺甲噁唑对急性淋巴细胞白血病化疗后肺孢子菌肺炎的预防作用[J].医学信息,2020,33(12):135-137,140.[doi:10.3969/j.issn.1006-1959.2020.12.042]
　LIU Jie-yu,FANG Zhi-hui,LI Wen-ke,et al.Preventive Effect of Compound Sulfamethoxazole on Pneumocystis Pneumonia After Chemotherapy in Acute Lymphoblastic Leukemia[J].Medical Information,2020,33(12):135-137,140.[doi:10.3969/j.issn.1006-1959.2020.12.042]
点击复制

复方磺胺甲噁唑对急性淋巴细胞白血病化疗后肺孢子菌肺炎的预防作用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年12期
页码:
135-137,140
栏目:
药物与临床
出版日期:
2020-06-15

文章信息/Info

Title:
Preventive Effect of Compound Sulfamethoxazole on Pneumocystis Pneumonia After Chemotherapy in Acute Lymphoblastic Leukemia
文章编号:
1006-1959（2020）12-0135-04
作者:
刘婕妤; 方智辉; 李文克; 等
（天津港口医院血液科，天津 300456）
Author(s):
LIU Jie-yu; FANG Zhi-hui; LI Wen-ke; et al
(Department of Hematology,Tianjin Port Hospital,Tianjin 300456,China)
关键词:
肺孢子菌肺炎; 复方磺胺甲噁唑; 急性淋巴细胞白血病
Keywords:
Pneumocystis pneumonia; Compound sulfamethoxazole; Acute lymphoblastic leukemia
分类号:
R563.1
DOI:
10.3969/j.issn.1006-1959.2020.12.042
文献标志码:
A
摘要:
目的 评价复方磺胺甲噁唑（TMP/SMX）对急性淋巴细胞白血病患者肺孢子菌肺炎（PJP）的预防作用。方法 选取2016年3月~2019年9月我院收治的42例急性淋巴细胞白血病患者为研究对象，采用随机数字表法分为对照组和试验组，每组21例。对照组采用常规化疗方案，试验组在对照组基础上给予复方磺胺甲噁唑预防治疗。比较两组疗效、生存分析、PJP发病率、病死率及不良反应。结果 试验组化疗后完全缓解率为66.67%，与对照组的71.42%比较，差异无统计学意义（P＞0.05）；两组疾病复发情况、3.5年总生存期率及无进展生存期率比较，差异无统计学意义（P＞0.05）；试验组应用TMP/SMX预防治疗后未发生PJP，对照组PJP发生率为23.81%，差异有统计学意义（P＜0.05）；试验组无PJP死亡患者，对照组PJP病死率40.00%，两组比较差异无统计学意义（P＞0.05）。两组在治疗期间毒副反应发生率比较，差异无统计学意义（P＞0.05）。结论 对于急性淋巴细胞白血病患者，预防应用复方磺胺甲噁唑有助于降低PJP的发病率，且不会增加化疗的毒副反应。
Abstract:
Objective To evaluate the preventive effect of compound sulfamethoxazole (TMP/SMX) on pneumocystis pneumonia (PJP) in patients with acute lymphoblastic leukemia.Methods 42 patients with acute lymphoblastic leukemia admitted to our hospital from March 2016 to September 2019 were selected as the research subjects. They were divided into a control group and a test group by random number table method, with 21 cases in each group. The control group used conventional chemotherapy regimen, and the test group was given compound sulfamethoxazole preventive treatment based on the control group. The efficacy, survival analysis, PJP morbidity, mortality and adverse reactions were compared between the two groups. Results The complete remission rate of the experimental group after chemotherapy was 66.67%, compared with 71.42% of the control group, the difference was not statistically significant (P＞0.05); the comparison of disease recurrence,the 3.5-year overall survival rate and progression-free survival rate between the two groups was not statistically significant significance (P＞0.05); PJP did not occur in the experimental group after TMP/SMX prophylaxis and treatment, the incidence of PJP in the control group was 23.81%, the difference was statistically significant (P＜0.05); there were no PJP deaths in the experimental group, PJP in the control group The case fatality rate was 40.00%,the difference was not statistically significant (P＞0.05). There was no statistically significant difference in the incidence of side effects during treatment between the two groups (P＞0.05).Conclusion For patients with acute lymphoblastic leukemia, the preventive application of compound sulfamethoxazole can help reduce the incidence of PJP, and will not increase the side effects of chemotherapy.

参考文献/References:

[1]Advani A.Acute lymphoblastic leukemia(ALL)[J].Bailliè re s Best Practice and Research in Clinical Haematology,2017,30(3):173-174.[2]Maschmeyer G,Helweg-Larsen J,Pagano L,et al.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J].J Antimicrob Chemother,2016,71(9):2405-2413. [3]Wang S,He G.2016 Revision to the WHO classification of acute lymphoblastic leukemia[J].J Transl Int Med,2016,4(4):147-149. [4]中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会白血病淋巴瘤学组．中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志,2016,37(10):837-845.[5]Jabbour E,Short NJ,Ravandi F,et al.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study[J].Lancet Haematol,2018,5(12):e618-e627. [6]Hitzenbichler F,Mohr A,Salzberger B.Pneumocystis-jirovecii-Pneumonie - eine opportunistische Infektion im Wandel [Pneumocystis jirovecii pneumonia-an opportunistic infection undergoing change] [J].Internist (Berl),2019,60(7):669-677. [7]Cordonnier C,Alanio A,Cesaro S,et al.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors’ response[J].J Antimicrob Chemother,2017,72(4):1266-1268. [8]Roux A,Canet E,Valade S,et al.Pneumocystis jirovecii pneumonia in patients with or without AIDS,France[J].Emerging Infectious Diseases,2014,20(9):1490-1497. [9]Cooley L,Dendle C,Wolf J,et al.Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies,2014[J].Intern Med J,2014,44(12b):1350-1363. [10]Cordonnier C,Cesaro S,Maschmeyer G,et al.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients[J].J Antimicrob Chemother,2016,71(9):2379-2385. [11]Nazir HF,Elshinawy M,Al Rawas A,et al.Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia[J].J Pediatr Hematol Oncol,2017,39(3):203-208.

相似文献/References:

[1]刘 璇,徐晓玲.肾移植受者罹患肺孢子菌肺炎的危险因素分析[J].医学信息,2021,34(07):74.[doi:10.3969/j.issn.1006-1959.2021.07.020]
　LIU Xuan,XU Xiao-ling.Analysis of Risk Factors for Pneumocystis Pneumonia in Kidney Transplant Recipients[J].Medical Information,2021,34(12):74.[doi:10.3969/j.issn.1006-1959.2021.07.020]

更新日期/Last Update: 1900-01-01